CO2018011355A2 - Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes - Google Patents
Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenesInfo
- Publication number
- CO2018011355A2 CO2018011355A2 CONC2018/0011355A CO2018011355A CO2018011355A2 CO 2018011355 A2 CO2018011355 A2 CO 2018011355A2 CO 2018011355 A CO2018011355 A CO 2018011355A CO 2018011355 A2 CO2018011355 A2 CO 2018011355A2
- Authority
- CO
- Colombia
- Prior art keywords
- dengue
- virus
- compositions
- den
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
- C12N2770/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24164—Methods of inactivation or attenuation by serial passage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322167P | 2016-04-13 | 2016-04-13 | |
| PCT/IB2017/052160 WO2017179017A1 (en) | 2016-04-13 | 2017-04-13 | Compositions and methods of vaccination against dengue virus in children and young adults |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018011355A2 true CO2018011355A2 (es) | 2018-11-13 |
Family
ID=58671740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0011355A CO2018011355A2 (es) | 2016-04-13 | 2018-10-24 | Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes |
Country Status (14)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6818548B2 (ja) * | 2013-03-15 | 2021-01-20 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | ワクチンにおけるデングウイルスキメラ構築物に関する組成物および方法 |
| KR102611235B1 (ko) * | 2016-04-13 | 2023-12-08 | 다케다 백신즈 인코포레이티드 | 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법 |
| TWI766876B (zh) * | 2016-08-03 | 2022-06-11 | 美商武田疫苗股份有限公司 | 用於與經改良之調配物一起穩定黃病毒的組成物及方法 |
| CN111447947B (zh) | 2017-12-07 | 2024-01-12 | 默沙东有限责任公司 | 登革病毒疫苗组合物的制剂 |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| PE20211545A1 (es) * | 2018-09-05 | 2021-08-16 | Takeda Vaccines Inc | Dosis unitaria de vacuna contra el dengue y administracion de esta |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| CN114555113A (zh) * | 2019-08-16 | 2022-05-27 | 武田疫苗股份有限公司 | 用于预防登革热和甲型肝炎的方法 |
| US20240076631A2 (en) | 2020-02-27 | 2024-03-07 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| EP3892737A1 (en) * | 2020-04-09 | 2021-10-13 | Takeda Vaccines, Inc. | Qualitative and quantitative determination of single virus haplotypes in complex samples |
| WO2023147337A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| US20250177511A1 (en) | 2022-02-15 | 2025-06-05 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| WO2023215383A1 (en) | 2022-05-04 | 2023-11-09 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| WO2024086681A1 (en) * | 2022-10-20 | 2024-04-25 | Takeda Vaccines, Inc. | A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype |
| EP4612495A1 (en) * | 2022-11-02 | 2025-09-10 | Takeda Vaccines, Inc. | A method for determining the infectivity of a virus |
| EP4375381A1 (en) | 2022-11-18 | 2024-05-29 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
| WO2024118740A1 (en) | 2022-11-29 | 2024-06-06 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2338508T3 (en) * | 2002-05-03 | 2018-05-28 | The Government Of The Us Secretary Department Of Health And Human Services | rDEN3 / 4delta30 (ME), rDEN2 / 4delta30 (ME) or rDEN1 / 4delta30 (ME) recombinant chimeric Dengue virus containing a 30 nucleotide deletion (delta30) in a section of the 3 'untranslated region of Dengue type 4 genome, where The 30-nucleotide deletion corresponds to the TL2 hairpin structure |
| US8968996B2 (en) * | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| MX343172B (es) | 2009-06-01 | 2016-10-26 | Takeda Vaccines Inc | Composiciones y metodos para administracion de vacunas contra virus del dengue. |
| EP2771366A4 (en) * | 2011-10-25 | 2015-06-03 | Florida Gulf Coast University Board Of Trustees | VACCINES AND METHOD FOR PRODUCING A VACCINE FOR INDUCING IMMUNITY AGAINST ALL SERGENT TYPES OF THE DENGUE VIRUS |
| TW201402143A (zh) * | 2012-06-10 | 2014-01-16 | Inviragen Inc | 抗登革熱病毒疫苗之組成物及投藥方法 |
| US20150196631A1 (en) * | 2012-07-24 | 2015-07-16 | Sanofi Pasteur | Vaccine compositions |
| TW201920677A (zh) * | 2012-11-08 | 2019-06-01 | 美商武田疫苗股份有限公司 | 登革熱病毒血清型４型之建構物的組成物、方法及用途 |
| US9878031B2 (en) | 2012-12-14 | 2018-01-30 | Takeda Vaccines, Inc. | Compositions, methods of administration and uses for trivalent dengue virus formulations |
| JP6818548B2 (ja) * | 2013-03-15 | 2021-01-20 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | ワクチンにおけるデングウイルスキメラ構築物に関する組成物および方法 |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| KR102611235B1 (ko) * | 2016-04-13 | 2023-12-08 | 다케다 백신즈 인코포레이티드 | 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법 |
| US11464815B2 (en) * | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| PE20211545A1 (es) * | 2018-09-05 | 2021-08-16 | Takeda Vaccines Inc | Dosis unitaria de vacuna contra el dengue y administracion de esta |
-
2017
- 2017-04-13 KR KR1020187032733A patent/KR102611235B1/ko active Active
- 2017-04-13 JP JP2018553428A patent/JP2019511533A/ja active Pending
- 2017-04-13 AU AU2017250696A patent/AU2017250696A1/en not_active Abandoned
- 2017-04-13 SG SG10201913383RA patent/SG10201913383RA/en unknown
- 2017-04-13 MX MX2018012459A patent/MX2018012459A/es unknown
- 2017-04-13 MY MYPI2018001735A patent/MY192806A/en unknown
- 2017-04-13 SG SG11201808906RA patent/SG11201808906RA/en unknown
- 2017-04-13 CN CN202510170711.1A patent/CN120392993A/zh active Pending
- 2017-04-13 WO PCT/IB2017/052160 patent/WO2017179017A1/en not_active Ceased
- 2017-04-13 BR BR112018071087-3A patent/BR112018071087A2/pt unknown
- 2017-04-13 CA CA3020484A patent/CA3020484A1/en active Pending
- 2017-04-13 PH PH1/2018/502175A patent/PH12018502175B1/en unknown
- 2017-04-13 CN CN201780028507.XA patent/CN109069615B/zh active Active
- 2017-04-13 US US16/093,385 patent/US11007261B2/en active Active
- 2017-04-13 EP EP17721858.3A patent/EP3442571A1/en active Pending
-
2018
- 2018-10-24 CO CONC2018/0011355A patent/CO2018011355A2/es unknown
- 2018-11-19 AU AU2018267542A patent/AU2018267542B2/en active Active
-
2021
- 2021-04-13 US US17/229,109 patent/US20210236620A1/en not_active Abandoned
-
2022
- 2022-04-20 JP JP2022069423A patent/JP2022089964A/ja active Pending
-
2024
- 2024-03-21 JP JP2024044760A patent/JP2024071463A/ja not_active Withdrawn
- 2024-08-30 US US18/821,030 patent/US20250235522A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250235522A1 (en) | 2025-07-24 |
| KR102611235B1 (ko) | 2023-12-08 |
| CA3020484A1 (en) | 2017-10-19 |
| BR112018071087A2 (pt) | 2019-02-26 |
| WO2017179017A1 (en) | 2017-10-19 |
| PH12018502175B1 (en) | 2023-12-06 |
| EP3442571A1 (en) | 2019-02-20 |
| AU2017250696A1 (en) | 2018-11-22 |
| AU2018267542B2 (en) | 2020-06-18 |
| PH12018502175A1 (en) | 2019-10-28 |
| KR20180137514A (ko) | 2018-12-27 |
| US20190381163A1 (en) | 2019-12-19 |
| SG10201913383RA (en) | 2020-03-30 |
| JP2022089964A (ja) | 2022-06-16 |
| AU2018267542A1 (en) | 2018-12-13 |
| JP2024071463A (ja) | 2024-05-24 |
| CN109069615B (zh) | 2025-03-04 |
| JP2019511533A (ja) | 2019-04-25 |
| US20210236620A1 (en) | 2021-08-05 |
| MY192806A (en) | 2022-09-09 |
| US11007261B2 (en) | 2021-05-18 |
| CN120392993A (zh) | 2025-08-01 |
| SG11201808906RA (en) | 2018-11-29 |
| CN109069615A (zh) | 2018-12-21 |
| MX2018012459A (es) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018011355A2 (es) | Composiciones y métodos de vacunación contra virus de dengue en niños y adultos jóvenes | |
| AR093421A1 (es) | Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4 | |
| ECSP23013715A (es) | Composiciones y métodos de construcciones quiméricas del virus del dengue en vacunas | |
| Khetarpal et al. | Dengue fever: causes, complications, and vaccine strategies | |
| PE20140646A1 (es) | Vacuna de virus de dengue inactivado | |
| JP2019511533A5 (cg-RX-API-DMAC7.html) | ||
| Huang et al. | Vaccine development for mosquito-borne viral diseases | |
| JP2016513970A5 (cg-RX-API-DMAC7.html) | ||
| CO6470882A2 (es) | Composiciones y metodos para administración de vacunas contra virus del dengue. | |
| MX2018010958A (es) | Vacuna para virus de zika atenuado vivo. | |
| JP2016504315A5 (cg-RX-API-DMAC7.html) | ||
| BR112018077540A2 (pt) | vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado | |
| BR112016002354A2 (pt) | composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit | |
| JP2019511221A5 (cg-RX-API-DMAC7.html) | ||
| PH12021550785A1 (en) | Virus vaccine | |
| BR112016029201A2 (pt) | vírus do oeste do nilo/dengue quiméricos e métodos de uso | |
| Wei et al. | Recent progress in dengue vaccine development | |
| Pulmanausahakul et al. | The development of flavivirus vaccines | |
| Stovba et al. | Using the vaccinia virus MVA strain for developing recombinant vector vaccines against current arboviral infections | |
| BR0010969A (pt) | Vacina polivalente antivìrus da dengue | |
| AR094238A1 (es) | Composicion vacunal contra el virus dengue | |
| TH170668A (th) | องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน |